¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"oxygen enhancement ratio"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • biological oxygen demand
    »ý¹°ÇÐÀû»ê¼Ò¿ä±¸·®
  • compressed oxygen
    ¾ÐÃà»ê¼Ò
  • chemical oxygen demand
    È­ÇÐÀû»ê¼Ò¿ä±¸·®
  • dissolved oxygen
    ¿ëÇØ»ê¼Ò
  • dissolved oxygen determination
    ¿ëÁ¸»ê¼Ò·®ÃøÁ¤, ³ìÀº»ê¼Ò·®ÃøÁ¤
  • fraction of inspired oxygen
    ÈíÀÔ»ê¼Ò³óµµ
  • heavy oxygen
    Áß»ê¼Ò
  • hemoglobin oxygen saturation
    Çì¸ð±Û·Îºó»ê¼ÒÆ÷È­µµ
  • hyperbaric oxygen
    °í¾Ð»ê¼Ò
  • hyperbaric oxygen therapy
    °í¾Ð»ê¼Ò¿ä¹ý
  • inspired oxygen fraction
    µé¼û»ê¼ÒºÐÀ², Èí±â»ê¼ÒºÐÀ²
  • liquid oxygen
    ¾×ü»ê¼Ò
  • maximum oxygen debt
    ÃÖ´ë»ê¼ÒºÎä
  • mean venous oxygen content
    Æò±ÕÁ¤¸ÆÇ÷»ê¼Ò·®
  • oxygen
    »ê¼Ò
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • active oxygen
    Ȱµ¿»ê¼Ò, Ȱ¼º»ê¼Ò
  • hyperbaric oxygen
    °í¾Ð»ê¼Ò
  • saturation dissolved oxygen
    Æ÷È­¿ëÇØ»ê¼Ò·®
  • oxygen requirement
    »ê¼Ò¿ä±¸·®
  • arterial oxygen saturation
    µ¿¸ÆÇ÷»ê¼ÒÆ÷È­µµ
  • oxygen saturation
    »ê¼ÒÆ÷È­µµ
  • arterial oxygen tension
    µ¿¸ÆÇ÷»ê¼ÒºÐ¾Ð
  • home oxygen therapy
    °¡Á¤»ê¼Ò¿ä¹ý
  • oxygen tension
    »ê¼ÒºÐ¾Ð, »ê¼ÒÀå·Â
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • periventricular enhancement
    ³ú½ÇÁÖÀ§Á¶¿µÁõ°­
  • rim enhancement
    Å×Áõ°­
  • ring enhancement
    °í¸®Á¶¿µÁõ°­
  • active oxygen
    Ȱµ¿»ê¼Ò, Ȱ¼º»ê¼Ò
  • alveolar oxygen pressure
    ÆóÆ÷»ê¼Ò¾Ð
  • alveolar-arterial oxygen gradient
    ÆóÆ÷µ¿¸Æ°£»ê¼ÒºÐ¾ÐÂ÷
  • arterial oxygen saturation
    µ¿¸ÆÇ÷»ê¼ÒÆ÷È­µµ
  • arterial oxygen tension
    µ¿¸ÆÇ÷»ê¼ÒºÐ¾Ð
  • oxygen aeration
    »ê¼ÒÅë±â
  • oxygen apnea
    »ê¼Ò¹«È£Èí
  • biochemical oxygen demand
    »ý¹°È­ÇÐÀû»ê¼Ò¿ä±¸·®
  • biological oxygen demand
    »ý¹°ÇÐÀû»ê¼Ò¿ä±¸·®
  • chemical oxygen demand
    È­Çлê¼Ò¿ä±¸·®
  • compressed oxygen
    ¾ÐÃà»ê¼Ò
  • mean venous oxygen content
    Æò±ÕÁ¤¸ÆÇ÷»ê¼Ò·®
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Hemoglobin-oxygen equilibrium curve
    Çì¸ð±Û·Îºó-»ê¼Ò°î¼±
  • PAO2 => alveolar oxygen pressure
    ÆóÆ÷(øËøà)»ê¼Ò¾Ð
  • So2=>oxygen saturation
    »ê¼ÒÆ÷È­µµ
  • active oxygen
    Ȱ¼º»ê¼Ò(üÀàõß«áÈ).
  • altered oxygen affinity
    »ê¼Òģȭ¼º º¯¼º
  • alveolar arterial oxygen gradient
    ÆóÆ÷µ¿¸Æ°£ »ê¼ÒºÐ¾ÐÂ÷.
  • alveolar-arterial oxygen difference
    ÆóÆ÷-µ¿¸Æ »ê¼ÒÂ÷ÀÌ
  • alveolar-arterial oxygen gradient
    ÆóÆ÷µ¿¸Æ°£ »ê¼ÒºÐ¾ÐÂ÷
  • arterial blood oxygen tension
    µ¿¸ÆÇ÷»ê¼Ò Àå·Â.
  • arterial oxygen content
    µ¿¸ÆÇ÷»ê¼ÒÇÔÀ¯·®
  • arterial oxygen saturation
    µ¿¸ÆÇ÷ »ê¼ÒÆ÷È­µµ
  • arterial oxygen tension
    µ¿¸ÆÇ÷»ê¼ÒºÐ¾Ð, µ¿¸ÆÇ÷»ê¼ÒÀå·Â
  • arterial oxygen tension
    µ¿¸ÆÇ÷ »ê¼ÒºÐ¾Ð
  • arterial-venous oxygen content difference
    µ¿¸Æ-Á¤¸Æ»ê¼Ò¿ëÀûÂ÷ÀÌ
  • arterial-venous oxygen difference
    µ¿¸Æ-Á¤¸Æ »ê¼ÒÂ÷ÀÌ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • immunological enhancement
    ¸é¿ªÁõ°­.
  • inflow enhancement
    À¯ÀÔ Áõ°­
  • minimal enhancement
    ¹Ì¹ÌÇÑ Á¶¿µÁõ°­, °æµµÀÇ Á¶¿µÁõ°­
  • paradoxical enhancement
    ¿ª¼³Àû Á¶¿µÁõ°­
  • paramagnetic proton relaxation enhancement
    »óÀÚ¼º ¾çÀÚ ÀÌ¿Ï Áõ°­
  • peripheral linear enhancement
    ¸»ÃÊ ¼±Çü Á¶¿µÁõ°­
  • peripheral rim enhancement
    Å׵θ® Á¶¿µÁõ°­
  • postanodal enhancement
    ¾ç±ØÈÄÁõ°­.
  • postanodal enhancement
    ¾ç±ØÈÄÁõ°­(åÕпý­ñòË­)
  • posterior echo enhancement
    ÈÄ¹æ ¿¡ÄÚ Áõ°­, ÈÄ¹æ ¸Þ¾Æ¸®Áõ°­
  • posterior echo enhancement
    ÈĹæ (ý­Û°) ¿¡ÄÚ Áõ°­ (ñòË­), ÈĹæ (ý­Û°) ¸Þ¾Æ¸® ?
  • proton relaxation enhancement
    ¾çÀÚ ÀÌ¿Ï Áõ°­
  • rapid acquisition with relaxation enhancement (RARE)
    ±Þ¼Ó ȹµæ ÀÌ¿Ï Áõ°­
  • rim enhancement
    Å׵θ® Á¶¿µÁõ°­
  • ring enhancement
    ȯ»ó Á¶¿µÁõ°­
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • oxygen electrode
    »ê¼ÒÀü±Ø(ß«áÈï³Ð¿)
  • oxygen saturation
    »ê¼ÒÆ÷È­(ß«áÈøéûú)
  • oxygen saturation curve
    »ê¼ÒÆ÷È­°î¼±(ß«áÈøéûúÍØàÊ)
  • oxygen transferase
    "»ê¼Ò Æ®·£½ºÆÛ·¹À̽º, »ê¼ÒÀüÀÌÈ¿¼Ò(ß«áÈï®ì¹ý£áÈ)"
  • oxygen transport
    »ê¼Ò¿î¹Ý(ß«áÈê¡Úæ)
  • absorption ratio
    Èí¼öÀ² (ýåâ¥ëÒ)
  • acceptor-control ratio
    ¼ö¿ëü Á¦¾îÀ² (â¥é»ô÷ ð¤åÙëÒ)
  • affinity ratio
    ģȭºñ(öÑûúÝï)
  • A/G ratio
    A/G ºñ (Ýï)
  • albumin/globulin ratio
    ¾ËºÎ¹Î/±Û·ÎºÒ¸° ºñ(Ýï)
  • asymmetry ratio
    ºÒ±Õµîºñ (ÝÕгÔõÝï)
  • A+T/G+C ratio
    A+T/G+C ºñ (Ýï)
  • base-pair ratio
    ¿°±â¦ ºñ(Ýï)
  • base ratio
    ¿°±âºñ(ç¤ÐñÝï)
  • channels ratio method
    ä³Î ºñÀ²¹ý(Ýï×ËÛö)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • CE [=contrast enhancement]
    Á¶¿µÁõ°­
  • contrast enhancement [=CE]
    Á¶¿µÁõ°­
  • contrast enhancement scan
    Á¶¿µÁõ°­½ºÄµ
  • dense enhancement
    °­ÇÑ Á¶¿µÁõ°­
  • edge enhancement
    º¯¿¬Áõ°­
  • enhancement
    Áõ°­
  • flow related enhancement
    À¯µ¿°ü·ÃÁõ°­
  • gradient echo technique magnetic susceptibility proton relaxation enhancement
    °æ»ç¿¡ÄÚ¹ý±âÈ­À²¼ºÀÚÀÌ¿ÏÁõ°­
  • inflow enhancement
    À¯ÀÔÁõ°­
  • minimal enhancement
    ¹Ì¹ÌÇÑÁ¶¿µÁõ°­, °æµµÀÇÁ¶¿µÁõ°­
  • paradoxical enhancement
    ¿ª¼³ÀûÁ¶¿µÁõ°­
  • paramagnetic proton relaxation enhancement
    »óÀÚ¼º¾çÀÚÀÌ¿ÏÁõ°­
  • peripheral linear enhancement
    ¸»Ãʼ±ÇüÁ¶¿µÁõ°­
  • peripheral rim enhancement
    Å׵θ®Á¶¿µÁõ°­
  • posterior echo enhancement
    ÈĹ濡ÄÚÁõ°­, ÈĹæ¸Þ¾Æ¸®Áõ°­
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
L/S lactase/sucrase [ratio]; lecithin/ sphingomyelin [ratio]; lipid/saccharide [ratio]; longitudinal sec...
FIO2 forced inspiratory oxygen; fractional concentration of oxygen in inspired gas
HO hand orthosis; heterotopic ossification; high oxygen; hip orthosis; history of; Holt-Oram [syndrome]...
O2 both eyes; diatomic oxygen; molecular oxygen
PaO2 partial oxygen tension in arterial blood; partial pressure of oxygen in arterial blood
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
L/S ratio Lecithin/sphingomyelin ratio
ADE Antibody-dependent enhancement
CE Contrast enhancement
EF Enhancement factors
LTE Long-term enhancement
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • body-weight ratio
    üÁß ½ÅÀå ºñ
  • cardiothoracic ratio
    ½ÉÈäºñ, ½ÉÈä°û ºñ, ½ÉÈä °è¼ö
  • cell color ratio
    Ç÷±¸»ö¼Òºñ, ÀûÇ÷±¸ »ö¼Òºñ
  • child woman ratio
    ¸ð¾Æ ºñÀ²
  • crown-root ratio
    Ä¡°ü´ë Ä¡±Ùºñ
  • curative ratio
    Ä¡À¯À²
  • death ratio
    »ç¸Áºñ
    µ¿ÀǾî=
  • effective ratio
    À¯È¿À²
    ¾î´À ÇѰè±îÁö´Â ¾àÁ¦ ¿ë·®°ú À¯È¿À²Àº ºñ·ÊÇÑ´Ù. ÇѰè À̻󿡼­´Â ºÎÀÛ¿ëÀÌ ³ªÅ¸³­´Ù.
  • expansion ratio
    ÆØÃ¢ºñ
  • innervation ratio
    ½Å°æ Áö¹è ºñ
  • magnetization transfer ratio
    ÀÚÈ­ Àü´Þ ºñÀ²
  • mercuryalloy ratio
    ¼öÀº Çձݺñ
  • monocyte lymphocyte ratio
    ´Ü±¸ ¸²ÇÁ±¸ºñ
  • optimal ratio
    ÃÖÀûºñ
  • optimum ratio
    ÃÖÀûºñ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
carbon-oxygen ligases <enzyme> Enzymes that catalyze the joining of two molecules by the formation of a carbon-oxygen bond.
Registry number: EC 6.1
(12 Dec 1998)
carbon-oxygen lyases <enzyme> Enzymes that catalyze the cleavage of a carbon-oxygen bond by means other than hydrolysis or oxidation.
Registry number: EC 4.2
(12 Dec 1998)
reactive oxygen species Reactive intermediate oxygen species including both radicals and non-radicals. These substances are constantly formed in the human body and have been shown to kill bacteria and inactivate proteins, and have been implicated in a number of diseases. Scientific data exist that link the reactive oxygen species produced by inflammatory phagocytes to cancer development.
(12 Dec 1998)
chemical oxygen demand The amount of dissolved oxygen required to combine with chemicals in wastewater. A measure of the oxygen equivalent of that portion of organic matter that is susceptible to oxidation by a strong chemical oxidizing agent.
(05 Dec 1998)
rubredoxin-oxygen oxidoreductase <enzyme> Contains fad and a new type of haem; site of oxygen reduction to water by desulfovibrio gigas coupled with NADH oxidation
Registry number: EC 1.9.3.-
Synonym: rubredoxin oxidase
(26 Jun 1999)
phosphorus-oxygen lyases <enzyme> Enzymes that catalyze the cleavage of a phosphorus-oxygen bond by means other than hydrolysis or oxidation.
Registry number: EC 4.6
(12 Dec 1998)
critical dissolved oxygen concentration <biology> The minimum concentration of oxygen in the water needed for the growth of a culture which has been submerged, where oxygen is the limiting factor to the growth of the culture.
(09 Oct 1997)
heavy oxygen A stable oxygen isotope making up 0.20% of natural oxygen; used in mass spectrometry and in NMR studies of tissue.
Synonym: heavy oxygen.
(05 Mar 2000)
home oxygen therapy A form of oxygen that is typically delivered via nasal cannula. Commonly provided to those with severe heart or lung disease.
See: chronic obstructive pulmonary disease.
(27 Sep 1997)
hyperbaric oxygen High pressure oxygen, oxygen at a pressure greater than 1 atmosphere.
See: hyperbaric oxygenation.
Singlet oxygen, an excited or higher energy form of oxygen characterised by the spin of a pair of electrons in opposite directions, whereas electron spin is unidirectional in normal molecular oxygen Because of its great reactivity, singlet oxygen is a probable intermediate in most photo-oxidation reactions. Although it exists for no more than 0.1 sec, it may react with atmospheric pollutants to foster smog formation and may have harmful biological effects.
Triplet oxygen, the normal unexcited state of O2 in the atmosphere, in which the unpaired pair of electrons are so displaced that their magnetic fields are oriented in the same direction, resulting in paramagnetism; each of the heat-generated spectral lines of such oxygen can be split by a magnetic field into a triplet.
Compare: singlet oxygen.
(05 Mar 2000)
hyperbaric oxygen therapy <physiology> A pressurised chamber that allows for the delivery of oxygen in higher concentrations for therapeutic benefit.
Useful in the treatment of severe burns, peripheral vascular disease, carbon monoxide poisoning and decompression illness.
(04 Mar 1998)
singlet oxygen An energised but uncharged form of oxygen that is produced in the metabolic burst of leucocytes and that can be toxic to cells.
(18 Nov 1997)
dissolved oxygen <biochemistry> The concentration of oxygen dissolved in water, expressed in mg/l or as percent saturation, where saturation is the maximum amount of oxygen that can theoretically be dissolved in water at a given altitude and temperature.
(11 Jan 1998)
oxygen 1. <chemistry> A colourless, tasteless, odorless, gaseous element occurring in the free state in the atmosphere, of which it forms about 23 per cent by weight and about 21 per cent by volume, being slightly heavier than nitrogen. Symbol O. Atomic weight 15.96.
It occurs combined in immense quantities, forming eight ninths by weight of water, and probably one half by weight of the entire solid crust of the globe, being an ingredient of silica, the silicates, sulphates, carbonates, nitrates, etc.
Oxygen combines with all elements (except fluorine), forming oxides, bases, oxyacid anhydrides, etc, the process in general being called oxidation, of which combustion is only an intense modification.
at ordinary temperatures with most substances it is moderately active, but at higher temperatures it is one of the most violent and powerful chemical agents known. It is indispensable in respiration, and in general is the most universally active and efficient element.
It may be prepared in the pure state by heating potassium chlorate. This element (called dephlogisticated air by Priestley) was named oxygen by Lavoisier because he supposed it to be a constituent of all acids. This is not so in the case of a very few acids (as hydrochloric, hydrobromic, hydric sulphide, etc), but these do contain elements analogous to oxygen in property and action. Moreover, the fact that most elements approach the nearer to acid qualities in proportion as they are combined with more oxygen, shows the great accuracy and breadth of Lavoisier's conception of its nature.
Pharmacologic action: Increases the supply of oxygen to ischemic tissues. It is the most effective agent in emergency cardiac care.
Uses: Always administer oxygen during emergency cardiac care.
Dose: Nasal cannula with oxygen flow of 4 liters per minute provides FiO2 of about 30%. Nasal cannula with oxygen flow of 6-8 liters per minute provides FiO2 of 35-40%. Venturi mask can provide higher and more precise oxygen concentrations.
Potential complications: Ensure that oxygen is being delivered. Carefully check all connections. Oxygen toxicity develops only after several days of exposure to high FiO2. Increased FiO2 may cause hypoventilation in COPD patients dependent on hypoxic ventilatory drive. This is very rare and simply requires starting at lower FiO2, careful observation, and assisted ventilation if necessary.
Origin: F. Oxygene, from Gr. Sharp, acid + root of to be born. So called because originally supposed to be an essential part of every acid.
(17 Mar 2000)
oxygen-15 A cyclotron-produced, positron-emitting radioisotope of oxygen with a half-life of 122.2 seconds; used in studies of respiratory function and in positron emission tomography.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • focal ratio
    =F-NUMBER
  • inverse ratio
    (¼ö)¹Ýºñ;¿ªºñ
  • mass ratio
    Áú·®ºñ (ÃßÁøºÎ¸¦ Á¦¿ÜÇÑ ·ÎÄÏ º»Ã¼¿¡ ´ëÇÑ ÃÑÁß·®ÀÇ ºñÀ²,ÃßÁø¾à ÃæÀüÀ²)
  • payout ratio
    ¹è´ç ¼ºÇâ
  • priceearnings ratio
    ÁÖ°¡ ¼öÀÍ·ü 9
  • ratio
    ºñ;ºñÀ²
  • respiratory quotient (ratio)
    È£Èí·ü;È£Èíºñ(³»¹ñ´Â ź»ê°¡½ºÀÇ ¾ç°ú ¿ÜºÎ·ÎºÎÅÍ Èí¼öÇÏ´Â »ê¼Ò·®°úÀÇ ºñ)
  • risk-benefit ratio
    À§Ç輺°ú ¼öÀͼº°úÀÇ ºñÀ²
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á